Evidence map›Paper›PMID 39680215›Full record

ArticleJournal of neurology2024

Prognostic factors affecting ALS progression through disease tollgates.

Haoran Wu, F Safa Erenay, Osman Y Özaltın, Özden O Dalgıç, Mustafa Y Sır, Qi-Ming He, Brian A Crum, Kalyan S Pasupathy, Pooled Resource Open-Access ALS Clinical Trials Consortium

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Haoran WuSchool of Business, Sun Yat-Sen University, Guangzhou, Guangdong, China.
F Safa Erenay *Department of Management Sciences and Engineering, University of Waterloo, Waterloo, ON, Canada.
Osman Y ÖzaltınE.P. Fitts Department of Industrial & Systems Engineering, NC State University, Raleigh, NC, USA.
Özden O DalgıçHarvard Medical School, Boston, MA, USA.
Mustafa Y SırMayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, USA.
Qi-Ming HeDepartment of Management Sciences and Engineering, University of Waterloo, Waterloo, ON, Canada.
Brian A Crum *Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. Crum.Brian@mayo.edu.
Kalyan S Pasupathy *Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, USA.
Pooled Resource Open-Access ALS Clinical Trials Consortium

Funding

NSERC (Natural Sciences and Engineering Research Council of Canada) 2017-04001NSERC (Natural Sciences and Engineering Research Council of Canada) 2018-06596
6 · The paper itself

Abstract

BACKGROUND AND

objectivesUnderstanding factors affecting the timing of critical clinical events in ALS progression.

methodsWe captured ALS progression based on the timing of critical events (tollgates), by augmenting 6366 patients' data from the PRO-ACT database with tollgate-passed information using classification. Time trajectories of passing ALS tollgates after the first visit were derived using Kaplan-Meier analyses. The significant prognostic factors were found using log-rank tests. Decision-tree-based classifications identified significant ALS phenotypes characterized by the list of body segments involved at the first visit.

resultsStandard (e.g., gender and onset type) and tollgate-related (phenotype and initial tollgate level) prognostic factors affect the timing of ALS tollgates. For instance, by the third year after the first visit, 80-100% of bulbar-onset patients vs. 43-48% of limb-onset patients, and 65-73% of females vs. 42-49% of males lost the ability to talk and started using a feeding tube. Compared to the standard factors, tollgate-related factors had a stronger effect on ALS progression. The initial impairment level significantly impacted subsequent ALS progression in a segment while affected segment combinations further characterized progression speed. For instance, patients with normal speech (Tollgate Level 0) at the first visit had less than a 10% likelihood of losing speech within a year, while for patients with Tollgate Level 1 (affected speech), this likelihood varied between 23 and 53% based on additional segment (leg) involvement.

conclusionsTollgate- and phenotype-related factors have a strong effect on the timing of ALS tollgates. All factors should be jointly considered to better characterize patient groups with different progression aggressiveness.

Indexed as

Amyotrophic Lateral SclerosisDisease ProgressionAgedFemaleHumansMaleMiddle AgedPrognosisAmyotrophic lateral sclerosis tollgatesDisease progressionKaplan–Meier analysisPrognostic factorsTime trajectory projection

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.